Platelet-Rich Plasma at the Time of Transvaginal Prolapse Surgery: A Double-Blind Randomized Placebo-Controlled Trial

View at publisher Summarise with VIRAT
Authors: Isuzu Meyer, Christina T. Blanchard, Lynda G. Ugwu, H. Richter
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Pelvic organ prolapse is a common and burdensome condition, with growing demand for safe and effective surgical approaches. While transvaginal native tissue repairs offer lower morbidity than mesh-augmented procedures, concerns persist regarding higher failure rates, particularly in the anterior compartment. Platelet-rich plasma (PRP), an autologous concentrate rich in bioactive growth factors, promotes tissue healing and regeneration and has been widely used in multiple surgical specialties. However, its application in gynecologic surgery remains underexplored. OBJECTIVE: To assess efficacy and safety of repair augmentation with autologous PRP injection into the fibromuscular connective tissue during anterior colporrhaphy over 12 months post native tissue prolapse surgery. METHODS: A double-blind, randomized, placebo-controlled pilot trial was conducted at a single tertiary-care center from July 2023 to August 2025, enrolling 60 women with symptomatic prolapse beyond the hymen undergoing transvaginal native tissue apical repair, including anterior colporrhaphy. Concomitant procedures for prolapse or urinary incontinence were permitted. Participants received intraoperative injections of either autologous PRP or placebo (normal saline) into the anterior compartment’s fibromuscular connective tissue in a grid-like pattern (0.5 mL-per-site, ≥1cm apart) following vaginal epithelium dissection. Intraoperatively, PRP was prepared from 15 mL of whole blood, centrifuged at 1500 rpm for 5 minutes using a commercial kit. The primary outcome was POP-Q point Ba over 12 months. Secondary outcomes included other POP-Q points, prolapse symptoms, retreatment, composite success (no prolapse beyond the hymen, no bulge symptoms, no retreatment), Pelvic Organ Prolapse Distress Inventory-6 (POPDI-6), Patient Global Impression of Improvement (PGI-I), and adverse events, assessed at 6 weeks, 3, 6, and 12 months. POP-Q point Ba was analyzed via multiple linear regression with a priori covariates (parity, vaginal estrogen, baseline variables with p

Fields of Study & Subjects

Pelvic floor disorders treatments Periodontal Regeneration and Treatments Uterine Myomas and Treatments

Publication details

Journal / source
Obstetrics and Gynecology
Volume
147
Issue
4S
Pages
5S–6S
Publication date
20 March 2026
Language
EN